IPXL Impax Laboratories, Inc.

+0  (0%)
Previous Close 13.55
Open 13.65
Price To book 1.55
Market Cap 969.42M
Shares 71,544,000
Volume 1,208,740
Short Ratio 1.32
Av. Daily Volume 2,144,400

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

CRL January 21 2013. Approved Jan 8 2015

Latest News

  1. Vetr Crowd Urges Sell For Impax Laboratories
  2. Impax to Present Data on Rytary® (Carbidopa and Levodopa) Extended-Release Capsules, Zomig® (Zolmitriptan) Nasal Spray and Investigational Drug IPX203 at the 2017 American Academy of Neurology® Annual Meeting
  3. Blog Coverage AbbVie's HCV Regimen Achieves 99% Cure Rate in Phase III Study
  4. Impac Secured Assets Corp. Mortgage Pass-Through Certificates, Series 2006-5 -- Moody's downgrades Impax's CFR to B2, outlook stable
  5. Impax to Report First Quarter 2017 Results on May 10, 2017
  6. Impax (IPXL) Up 35.3% Since Earnings Report: Can It Continue?
  7. Impax Announces Favorable Ruling Regarding Patent Validity for Zomig® (zolmitriptan) Nasal Spray
  8. Cellect Biotechnology and Impax Laboratories Post Solid Gains
  9. Impax Laboratories, Inc. breached its 50 day moving average in a Bullish Manner : IPXL-US : March 28, 2017
  10. Why Impax Labs Soared 37.3% Today
  11. Impax Gains 38% On CEO Appointment, Talk of Sale
  12. Skincare Makers Lead Biotech Movers
  13. Impax Board of Directors Appoints Paul M. Bisaro President and CEO
  14. Falling Earnings Estimates Signal Weakness Ahead for Impax Laboratories (IPXL)
  15. Impax Hires Morgan Stanley for Strategic Review, Possible Sale
  16. Impax Laboratories, Inc. :IPXL-US: Earnings Analysis: Q4, 2016 By the Numbers : March 7, 2017
  17. New Strong Sell Stocks for March 6th
  18. Impax (IPXL) Q4 Earnings in Line, Revenues Miss Estimates
  19. Impax Laboratories (IPXL) is Oversold: Can It Recover?
  20. Edited Transcript of IPXL earnings conference call or presentation 1-Mar-17 1:30pm GMT